Minoryx Therapeutics
- Company typePrivate
- Founded2011
- HeadquartersBarcelona, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Minoryx Therapeutics firmographics
Firmographics- Name
- Minoryx Therapeutics
- Legal name
- MINORYX THERAPEUTICS SL
- Website
- https://minoryx.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Minoryx Therapeutics industry classification
Industry- Product category
- Orphan CNS Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
- akta.pro secondary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where Minoryx Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Minoryx Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical product sales: Pre-revenue biotech company. Once approved, the company will generate revenue through sales of leriglitazone (brand name NEZGLYAL®). Neuraxpharm holds exclusive license for Europe, Sperogenix holds license for China. Revenue model will be traditional pharmaceutical product sales through prescription.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Minoryx Therapeutics product offering
Product offeringCore offering
Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel, orally bioavailable, selective PPAR gamma agonist for the treatment of orphan central nervous system (CNS) diseases. The lead indication is X-linked Adrenoleukodystrophy (X-ALD), with ongoing clinical programs in Friedreich's Ataxia and Rett syndrome. The company is pursuing EMA and FDA regulatory approval and licensing commercialization to regional pharmaceutical partners.
Product overview
Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel selective PPAR gamma agonist for orphan CNS diseases. The lead compound is being advanced through multiple clinical trial programs: ADVANCE (phase 2/3 in X-ALD adult patients), NEXUS (phase 2/3 in pediatric cALD), CALYX (phase 3 in adult progressive cALD), FRAMES (phase 2 in Friedreich's Ataxia), and TREE (phase 2a in Rett syndrome). The company has submitted a Marketing Authorization Application to EMA for cALD treatment.
Differentiator
Problem solved
Functional benefit
Brands
- NEZGLYAL®: Brand name for leriglitazone, the company's lead drug candidate for treatment of cerebral adrenoleukodystrophy (cALD)
Products and services
- Leriglitazone (MIN-102/NEZGLYAL®) Novel, orally bioavailable, selective PPAR gamma agonist with demonstrated brain penetration and favorable safety profile. Being developed for X-linked Adrenoleukodystrophy (X-ALD) including cerebral ALD (cALD) and adrenomyeloneuropathy (AMN), Friedreich's Ataxia, and Rett syndrome. Has been granted FDA Orphan Drug Designation, EMA Orphan Drug Designation, FDA Fast Track Designation, and FDA Rare Pediatric Disease Designation for X-ALD. Patents granted in EU and US covering multiple CNS indications until 2039.
Quantifiable outcome
- 35% of evaluable cALD patients met arrested disease criteria vs 10% expected from natural history (p<0.05) in NEXUS trial
- +4 more outcomes
Companies that use Minoryx Therapeutics
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
Minoryx Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Minoryx Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Neuraxpharm GroupcoreNeuraxpharm holds exclusive license for leriglitazone (NEZGLYAL®) in Europe. The partnership includes commercialization rights where Neuraxpharm prepares for and executes the commercial launch in Europe. Neuraxpharm is a leading European specialty pharmaceutical company focused on CNS disorders with direct presence in 20+ countries. They are backed by funds advised by Permira.
- SperogenixminorSperogenix has licensed rights to leriglitazone for China, handling commercialization in that market.
- Hôpital Universitaire La Pitié-SalpêtrièrecoreLed compassionate use study of leriglitazone in 13 adult cALD patients in France as part of early-access program through ANSM (French national drug agency). Study led by Prof. Fanny Mochel, published results in Brain journal.
- Hospital Sant Joan de DéucoreBarcelona hospital conducting TREE clinical trial in Rett syndrome under direction of Dr. Ángeles García Cazorla. Study funded by MCIN/AEI/10.13039/501100011033 and Union Europea-NextGenerationEU/PRTR.
- ALD ConnectminorPatient advocacy organization for X-linked Adrenoleukodystrophy. Kathleen O'Sullivan-Fortin, Co-Founder, expressed community excitement about CALYX trial commencement for adult cALD where few options are available.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
Minoryx Therapeutics competitors and assessment
Company assessmentDirect peers
- Poxel SA: French clinical-stage biotech focused on rare metabolic and neurological diseases, with direct overlap in Friedreich's Ataxia (PXL065 program). Comparable stage, European base, and indication focus to Minoryx.
- Stoke Therapeutics: Clinical-stage rare neurological disease biotech developing antisense oligonucleotide (ASO) therapies including zorevunersen for Dravet syndrome. Comparable late-stage rare CNS development profile and platform-based approach.
- bluebird bio: Obtained initial FDA approval for Skysona (elivaldogene autotemcel) gene therapy in early active cALD. Directly competes with leriglitazone for the same X-ALD patient population, representing Minoryx's most direct competitor in lead indication.
- Reata Pharmaceuticals: Developed Skyclarys (omaveloxolone) for Friedreich's Ataxia, the first FDA-approved therapy for FRDA. Direct competitor in Minoryx's second indication with an already-launched and approved product.
- MedDay Pharmaceuticals: Paris-based biotech that developed DILA-VR/serdexmethylphenidate for X-ALD-adjacent indications. Closely comparable European rare CNS biotech with similar indication footprint and development stage.
Broad incumbents
- Travere Therapeutics: Rare disease company with both metabolic and CNS pipeline programs including sparsentan and Filspari. Comparable mid-cap rare disease biotech with parallel platform expansion strategy.
- BioMarin Pharmaceutical: Established rare disease leader with multiple CNS and metabolic franchises (including Voxzogo). Larger incumbent with proven rare disease commercialization infrastructure across the same orphan prescribers Minoryx targets.
- Ionis Pharmaceuticals: Established antisense-based rare neurological disease developer with multiple approved therapies (Spinraza, Tegsedi, Wainua). Represents a broader incumbent in the rare CNS disease therapeutic space.
- Sage Therapeutics: CNS-focused biotech developing novel therapies for rare neurological disorders (Zulresso, Zurzuvae). Comparable CNS-focused clinical pipeline orientation and small-molecule orphan neurology focus.
- Ultragenyx Pharmaceutical: Commercial-stage rare disease biotech with approved products across metabolic and CNS indications. Comparable platform approach of single asset expanded across multiple rare diseases, with deeper financial resources.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Minoryx Therapeutics social profiles
Digital presenceMinoryx Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Minoryx Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Minoryx Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Minoryx Therapeutics funding detail
Funding detailFunding overview
Funding rounds11 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Minoryx Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Minoryx Therapeutics
What does Minoryx Therapeutics do?
Minoryx Therapeutics is a clinical-stage biotech company developing leriglitazone (MIN-102/NEZGLYAL®), a novel, orally bioavailable, selective PPAR gamma agonist for the treatment of orphan central nervous system (CNS) diseases. The lead indication is X-linked Adrenoleukodystrophy (X-ALD), with ongoing clinical programs in Friedreich's Ataxia and Rett syndrome. The company is pursuing EMA and FDA regulatory approval and licensing commercialization to regional pharmaceutical partners.
Is Minoryx Therapeutics a public or private company?
Minoryx Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Minoryx Therapeutics founded?
Minoryx Therapeutics was founded in 2011. It employs 11 to 50 people.
Where is Minoryx Therapeutics based?
Minoryx Therapeutics is headquartered in Barcelona, Spain, in the Europe region.
How does Minoryx Therapeutics make money?
One revenue line is on record: pharmaceutical product sales.
Who are Minoryx Therapeutics's main competitors?
Direct peers on record are Poxel SA, Stoke Therapeutics, bluebird bio, Reata Pharmaceuticals and MedDay Pharmaceuticals. Broad incumbents are Travere Therapeutics, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Sage Therapeutics and Ultragenyx Pharmaceutical.
Does Minoryx Therapeutics have an API?
No public API is recorded for Minoryx Therapeutics.
What industry is Minoryx Therapeutics in?
Minoryx Therapeutics's product category is Orphan CNS Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.